According to Savara Pharmaceuticals, the company has created a Clinical Advisory Board to provide advice on the development of AeroVanc vancomycin hydrochloride inhalation powder for the treatment of MRSA lung infections in patients with cystic fibrosis. The five members of the new board are:
- Michael P. Boyle, Associate Professor of Medicine and Director of the Adult Cystic Fibrosis Program at Johns Hopkins Medical Institutions, Baltimore, MD.
- Elliott C. Dasenbrook, Assistant Professor at Case Western Reserve University School of Medicine, Associate Director of the Adult Cystic Fibrosis Program at University Hospitals Case Medical Center, Cleveland, OH.
- Michael W. Konstan, Professor and Chairman of the Department of Pediatrics of Case Western Reserve University School of Medicine, Director of The LeRoy W. Matthews Cystic Fibrosis Center at University Hospitals Rainbow Babies and Children’s Hospital, Cleveland, OH.
- Felix Ratjen, Professor and Division Chief of Pediatric Respiratory Medicine at The Hospital for Sick Children, Co-leader of the Cystic Fibrosis Center at SickKids, Toronto, Canada.
- Grant Waterer, Professor and Head of Unit at the School of Medicine and Pharmacology Royal Perth Hospital Unit at the University of Western Australia, Perth, Australia.
Savara CEO Rob Neville commented, “We are very pleased to have this group of preeminent medical professionals join our Clinical Advisory Board. These individuals have decades of experience in the field and will provide invaluable counsel as we advance our AeroVanc clinical program this year and beyond. Their commitment to assist us in the development of AeroVanc speaks to the high importance our product may have for CF patients.”
The company says that it will begin enrollment in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of AeroVanc in early April at multiple sites in the US.
Read the Savara press release.
